GT Biopharma Announces Leadership Change
In a recent filing with the U.S. Securities and Exchange Commission, GT Biopharma, Inc. shared some important news regarding the responsibilities of one of its key officers. Dr. Jeffrey Miller has changed his roles from Consulting Chief Medical Officer and Consulting Chief Scientific Officer to become the Consulting Senior Medical Director.
Why the Change Happened
This alteration in Dr. Miller's role complies with a request from the University of Minnesota, where he primarily works. The university is ensuring it meets its conflict of interest policies as it gears up to start a Phase I clinical trial for GT Biopharma's groundbreaking GTB-3650 compound.
About GT Biopharma
GT Biopharma is a pharmaceutical company traded on The Nasdaq Stock Market LLC under the ticker GTBP, based in Delaware. The company specializes in pharmaceutical preparations, following the standards established in its SIC code 2834. Its main offices are located in the lively city of San Francisco, California.
Dr. Miller's Ongoing Involvement
Even with the new title of Consulting Senior Medical Director, Dr. Miller will still play an active role at GT Biopharma. His new responsibilities were validated in the recent 8-K filing, which noted there were no further changes among the executive team or to compensation structures.
GTB-3650 Receives FDA Approval
In recent developments, GT Biopharma has secured approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application concerning GTB-3650. This key approval allows the company to proceed with a Phase I clinical trial, which is expected to begin in the latter half of 2024. The trial will focus on the safety and effectiveness of GTB-3650 for patients with CD33 expressing hematologic malignancies, such as acute myeloid leukemia and high-risk myelodysplastic syndrome.
Fundraising Efforts
GT Biopharma has also initiated a registered direct offering along with a concurrent private placement, with plans to raise approximately $3.2 million in gross proceeds. This effort involves selling 740,000 shares of common stock at a price of $4.35 per share, alongside issuing warrants for the purchase of an additional 740,000 shares at the same price.
Frequently Asked Questions
What prompted the change in Dr. Miller's position at GT Biopharma?
The change was made in response to a request from the University of Minnesota, aimed at adhering to its conflict of interest policies.
What is GT Biopharma known for?
GT Biopharma is recognized for developing innovative treatments targeting hematologic malignancies, with a strong focus on pharmaceutical preparations.
What trial is GT Biopharma moving forward with?
The company is moving ahead with a Phase I clinical trial for GTB-3650, which is aimed at treating CD33 expressing hematologic malignancies.
When is the Phase I clinical trial expected to start?
The trial is set to commence in the second half of 2024.
How much funding is GT Biopharma expecting to generate?
GT Biopharma is looking to raise about $3.2 million through its recent registered direct offering and private placement.
